<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">atg7</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>ATG7</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>atg7</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=ATG7" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer-disease" style="color:#ef9a9a">ALZHEIMER DISEASE</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">AMYOTROPHIC LATERAL SCLEROSIS</a>, <a href="/wiki/ataxia" style="color:#ef9a9a">ATAXIA</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">823 edges</a></td>
</tr>
</table>
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">atg7</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>ATG7</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>atg7</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=ATG7" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer-disease" style="color:#ef9a9a">ALZHEIMER DISEASE</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">AMYOTROPHIC LATERAL SCLEROSIS</a>, <a href="/wiki/ataxia" style="color:#ef9a9a">ATAXIA</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">823 edges</a></td>
</tr>
</table>
ATG7 (Autophagy-Related Protein 7) is an essential E1-like activating enzyme that plays a central role in the execution of macroautophagy. It is critical for two ubiquitin-like conjugation systems that drive autophagosome formation: the ATG12-ATG5 conjugation system and the ATG8/LC3 lipidation system. Through these reactions, ATG7 catalyzes the activation and transfer of ubiquitin-like proteins to their respective targets, enabling the nucleation, expansion, and closure of the autophagosome[@komatsu2005].
In the nervous system, ATG7 is indispensable for neuronal homeostasis, synaptic function, and survival. Knockout of ATG7 in neurons leads to progressive neurodegeneration, accumulation of damaged organelles and protein aggregates, and premature death in animal models[@nishiyama2010]. Given the central role of autophagy in clearing misfolded proteins and damaged organelles, ATG7 dysfunction has been implicated in the pathogenesis of Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis[@schneider2021].
The protein is encoded by the ATG7 gene located on chromosome 3p25.3, and its dysfunction represents a critical bottleneck in the autophagy-lysosomal pathway that contributes to neurodegeneration in multiple proteinopathies.
ATG7 is a ~78 kDa protein that functions as the E1 enzyme for two distinct ubiquitin-like conjugation systems. The protein contains three functional domains critical to its enzymatic activity:
N-terminal Domain: Contains the active site cysteine residue (Cys-506) that forms a thioester intermediate with ubiquitin-like proteins during the activation process. This cysteine is absolutely essential for ATG7 function, and mutation completely abolishes autophagy[@mizushima2011].
Adenylation Domain: Binds ATP and the ubiquitin-like proteins (ATG12 and ATG8/LC3) during the activation step. This domain catalyzes the formation of an acyl-adenylate intermediate, releasing pyrophosphate.
C-terminal Domain: Mediates protein-protein interactions with the E2 enzymes (ATG3 and ATG10) and contains the flexible C-terminal tail that releases the activated ubiquitin-like protein for transfer to the E2.
The active site cysteine at position 506 is the nucleophilic residue that forms the thioester intermediate essential for enzymatic function. Structural studies have revealed the detailed mechanism of ATG7 catalysis, showing how it accommodates multiple substrates.
ATG7 catalyzes a two-step activation process for ubiquitin-like proteins, representing a unique variation on the classical E1 enzyme mechanism:
Step 1 - Adenylation: ATG7 binds ATP and the ubiquitin-like protein (either ATG12 or LC3/ATG8), forming an acyl-adenylate intermediate and releasing pyrophosphate. This step requires magnesium as a cofactor.
Step 2 - Thioester Transfer: The activated ubiquitin-like protein is transferred to the active site cysteine of ATG7, forming a thioester bond. This intermediate then undergoes nucleophilic attack by the E2 enzyme (ATG10 for ATG12, ATG3 for LC3), completing the transfer and regenerating the active enzyme.
Unlike classical E1 enzymes that function as monomers and typically act on only one ubiquitin-like protein, ATG7 uniquely handles multiple substrates. This dual specificity makes ATG7 a critical hub in autophagy regulation.
ATG7 activates ATG12, the first ubiquitin-like protein in the autophagy cascade. Following activation, ATG12 is transferred to ATG10 (the E2 enzyme) and conjugated to ATG5. The ATG12-ATG5 conjugate further forms a complex with ATG16L1, creating the ATG12-ATG5-ATG16L1 complex that functions as an E3 ligase for LC3 lipidation[@galluzzi2017].
The ATG12-ATG5-ATG16L1 complex localizes to the expanding edge of the phagophore (the nascent autophagosome) and promotes the recruitment of lipidated LC3 and cargo selection molecules. This conjugation system is essential for autophagosome nucleation and the recruitment of cargo receptors. The ATG12-ATG5 conjugate is formed early in autophagy induction and persists through autophagosome completion, with the entire complex disassembling upon autophagosome-lysosome fusion.
ATG7 is also essential for the activation of LC3 (and other ATG8 family proteins including GABARAP and GABARAPL1-3). Following activation by ATG7, LC3 is transferred to ATG3 (the E2 enzyme), which catalyzes its conjugation to phosphatidylethanolamine (PE) in the autophagosomal membrane. This lipidated form (LC3-II) is stably integrated into the autophagosome membrane and serves multiple functions:
Autophagosome formation proceeds through distinct stages, with ATG7 required for multiple steps:
ATG7 is required for steps 2-4, making it essential for the entire process of autophagosome biogenesis. Without ATG7, the autophagy cascade cannot proceed past initiation.
Neurons are highly post-mitotic cells with extreme longevity, making them particularly dependent on autophagy for cellular maintenance. ATG7-mediated autophagy is essential for[@maday2012]:
ATG7-mediated autophagy plays critical roles in synaptic function through multiple mechanisms[@knoblock2020]:
Synaptic Protein Turnover: Autophagy regulates the turnover of synaptic proteins at both presynaptic and postsynaptic sites, ensuring proper synaptic composition and function.
Synaptic Vesicle Recycling: Autophagy contributes to the clearance of aged or damaged synaptic vesicle components and supports synaptic vesicle pool maintenance.
Synaptic Plasticity: Activity-dependent autophagy modulates the availability of synaptic proteins during plasticity events, affecting learning and memory processes.
Synapse Elimination: During development and in disease, autophagy participates in synaptic pruning and elimination processes.
Defects in neuronal autophagy impair synaptic function and contribute to cognitive deficits in neurodegenerative disease models.
ATG7 function is critical for cognitive processes through its role in neuronal autophagy:
Hippocampal Function: ATG7 deficiency in neural stem cells leads to deficits in hippocampal neurogenesis and impaired memory formation[@nishiyama2010].
Long-Term Potentiation: Autophagy supports the protein turnover required for long-term changes in synaptic strength.
Memory Consolidation: Proper autophagy enables the remodeling of neuronal circuits during memory consolidation.
These findings highlight the importance of ATG7-mediated autophagy beyond basic cellular homeostasis to higher-order brain functions.
In Alzheimer's disease (AD), ATG7-mediated autophagy is compromised at multiple levels:
Autophagy Impairment: Early in AD, there is evidence of impaired autophagosome-lysosome fusion, accumulation of immature autophagic vacuoles, and reduced LC3 lipidation. These defects contribute to the accumulation of amyloid-beta and tau aggregates.
Amyloid Processing: Autophagy regulates the production and clearance of amyloid-beta. Impaired autophagy can lead to increased amyloid production and reduced clearance.
Tau Pathology: Autophagy is important for tau clearance. Reduced ATG7 activity may contribute to tau accumulation and propagation.
Synaptic Loss: Autophagy defects contribute to synaptic dysfunction and loss, early events in AD pathogenesis.
Therapeutic strategies to enhance autophagy, including ATG7 activation, are being explored for AD treatment.
Parkinson's disease (PD) is strongly linked to autophagy dysfunction, with ATG7 playing a central role[@yan2019]:
Alpha-Synuclein Clearance: Autophagy is a major pathway for alpha-synuclein degradation. Reduced ATG7 activity contributes to the accumulation of toxic alpha-synuclein aggregates.
Mitophagy: ATG7-mediated mitophagy is critical for removing damaged mitochondria, which accumulate in PD and contribute to neuronal death.
Lewy Body Formation: Impaired autophagy leads to accumulation of autophagic vacuoles containing alpha-synuclein, contributing to Lewy body formation.
Dopaminergic Neuron Vulnerability: The specific vulnerability of dopaminergic neurons in PD may relate to their high autophagic flux requirements and particular sensitivity to autophagy impairment.
Genetic links between autophagy genes and PD risk further support the importance of ATG7 in disease pathogenesis.
Huntington's disease (HD) involves mutant huntingtin protein that forms aggregates:
Aggregate Clearance: ATG7-mediated autophagy is important for clearing mutant huntingtin aggregates. Impaired autophagy contributes to aggregate accumulation.
Autophagy Dysregulation: Multiple components of the autophagy machinery are dysregulated in HD, including reduced ATG7 expression and activity.
Neuronal Dysfunction: Autophagy impairment contributes to the progressive neuronal dysfunction and loss characteristic of HD.
Enhancing autophagy through ATG7 activation has shown promise in HD models.
In ALS, autophagy dysfunction is observed:
Protein Aggregate Clearance: ALS involves accumulation of protein aggregates including TDP-43. ATG7-mediated autophagy is important for clearing these aggregates.
Mitochondrial Quality Control: Mitophagy defects contribute to mitochondrial dysfunction in ALS.
Motor Neuron Vulnerability: Motor neurons appear particularly sensitive to autophagy impairment, potentially contributing to their selective degeneration.
Mutations in several autophagy-related genes have been linked to familial ALS, highlighting the importance of this pathway in disease.
Therapeutic strategies targeting ATG7 and autophagy include:
ATG7 Activators: Small molecules that enhance ATG7 activity or expression to boost autophagy. Natural compounds like resveratrol and rapamycin (via mTOR inhibition) can enhance autophagy.
mTOR Inhibitors: Rapamycin and related compounds inhibit mTORC1, inducing autophagy and enhancing ATG7-dependent processes. However, mTOR inhibitors have complex effects and may not be suitable for chronic use.
Autophagy Inducers: Various compounds that induce autophagy through different mechanisms, including AMPK activators and Beclin1 enhancers.
Autophagy modulation for therapy faces several challenges:
Autophagy-UPS Crossover: The autophagy and ubiquitin-proteasome systems are interconnected, and modulating one affects the other.
Dose-Dependent Effects: Too much autophagy can be detrimental, causing excessive degradation of essential cellular components.
Cell-Type Specificity: Different cell types may respond differently to autophagy modulation.
Disease Stage: The optimal timing of intervention may vary depending on disease stage.
The ATG7 gene (also known as APG7L) is located on chromosome 3p25.3. It encodes a 678-amino acid protein with the characteristic E1 enzyme domain structure. The gene is expressed ubiquitously with high expression in brain tissue.
Genetic variants in ATG7 have been associated with:
Neurodegenerative Disease Risk: Some ATG7 polymorphisms have been associated with altered risk for Alzheimer's and Parkinson's diseases.
Autophagy Efficiency: Certain variants may affect autophagy efficiency and cellular stress responses.
Research continues to identify functional variants that influence disease susceptibility and progression.
Measures of autophagy activity as potential biomarkers include:
LC3 Conversion: The ratio of LC3-II to LC3-I, indicating the extent of LC3 lipidation.
p62/SQSTM1 Levels: p62 accumulates when autophagy is impaired, making it a marker of autophagy flux.
Autophagic Vacuoles: Electron microscopy can visualize autophagosomes and autolysosomes.
ATG7 Expression: ATG7 protein levels may indicate autophagy capacity.
Autophagy biomarkers may be useful for:
Disease Diagnosis: Assessing autophagy status may aid in diagnosis of neurodegenerative conditions.
Progression Monitoring: Changes in autophagy markers may reflect disease progression.
Therapeutic Monitoring: Autophagy modulation effects can be monitored through these markers.
Multiple models have been used to study ATG7 function:
Conditional Knockout Mice: Neuron-specific ATG7 knockout mice develop neurodegeneration with age, demonstrating the essential role of ATG7 in neuronal homeostasis.
Transgenic Models: Mouse models expressing mutant proteins (alpha-synuclein, tau, huntingtin) with ATG7 modification have been used to study autophagy modulation.
Knockin Models: Models with mutant ATG7 have been used to understand ATG7 function in vivo.
In vitro models include:
Primary Neurons: Cultured neurons from rodent or human origin for mechanistic studies.
iPSC-Derived Neurons: Patient-derived induced pluripotent stem cells differentiated into neurons for disease modeling.
Non-Neuronal Cells:HEK293, HeLa, and other cell lines for biochemical studies.
ATG7 occupies a central position in the autophagy-lysosomal pathway, serving as the E1 enzyme for both the ATG12-ATG5 and LC3 conjugation systems essential for autophagosome formation. In the nervous system, ATG7-mediated autophagy is critical for neuronal homeostasis, synaptic function, and cognitive processes. Dysfunction of ATG7 contributes to the pathogenesis of multiple neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis.
The essential nature of ATG7 for neuronal survival makes it both a critical therapeutic target and a challenging one. Strategies to enhance ATG7 activity or autophagy more broadly may offer neuroprotective benefits, though careful attention to dosing and cell-type specificity is required. The continued development of ATG7-targeted therapies, combined with biomarkers for patient selection and treatment monitoring, holds promise for addressing the autophagy dysfunction that contributes to neurodegenerative disease progression.
Future research directions include developing specific ATG7 activators, understanding cell-type-specific autophagy requirements, identifying optimal intervention points in disease progression, and developing biomarkers to guide therapeutic development.
The following diagram shows the key molecular relationships involving ATG7 Protein — Autophagy-Related Protein 7 discovered through SciDEX knowledge graph analysis: